Schizophrenia is a chronic, severe and disabling condition that affects almost 1% of the world's population and is associated with positive symptoms, negative symptoms and cognitive deficits. Despite the immense impact of the disease, patients and their physicians confront approved treatment options which do not successfully address the full range of symptoms and often give rise to significant side effects. In order to develop more effective medications, it is critical to target the pathology that underlies the disease, especially the pathological brain functioning that gives rise to negative symptoms and cognitive deficits.

Impaired cortical function, due at least in part to altered glutamate signaling, is a key event that likely contributes to schizophrenia. As a result, molecular mechanisms capable of regulating glutamate release represent novel and potentially promising treatment targets.

While other glutamate-based drug development efforts have shown promise, none seem capable of addressing the entire constellation of pathological changes associated with schizophrenia. Promentis believes that its approach takes the fullest account of the glutamatergic system and glutamatergic dysfunction that has been observed in the context of schizophrenia. Within this framework, Promentis is aggressively embarking on an effort to redefine what is possible in the treatment of schizophrenia and other psychiatric disorders.

LEARN MORE:
SCHIZOPHRENIA
GLUTAMATE, SCHIZOPHRENIA AND OTHER CNS DISORDERS